Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data.

Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies RR, Grönte D, Remington G.

J Clin Psychiatry. 2014 May;75(5):506-11. doi: 10.4088/JCP.13m08695.

PMID:
24569099
2.

"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial.

Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S.

J Clin Psychiatry. 2011 Aug;72(8):1042-8. doi: 10.4088/JCP.09m05866yel. Epub 2010 Sep 7.

PMID:
20868639
3.

[Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].

Bartkó G, Trixler M, Bitter I, Degrell I, Füredi J, Faludi G; Ziprasidonra Váltást Vizsgáló Munkacsoport.

Neuropsychopharmacol Hung. 2006 Dec;8(4):201-9. Hungarian.

PMID:
17211055
4.

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG.

Arch Gen Psychiatry. 1997 Jun;54(6):549-57.

PMID:
9193196
5.

Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia.

Takeuchi H, Fervaha G, Lee J, Agid O, Remington G.

Eur Neuropsychopharmacol. 2015 Mar;25(3):295-302. doi: 10.1016/j.euroneuro.2014.12.008. Epub 2015 Jan 9.

PMID:
25649680
6.

Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.

Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, Lieberman J.

Schizophr Res. 2009 Aug;113(1):12-8. doi: 10.1016/j.schres.2009.06.002.

PMID:
19545976
7.

[Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial].

Jarema M, Olajossy M, Chrzanowski W, Araszkiewicz A, Landowski J, Rybakowski J, Bilikiewicz A, Bomba J, Debowska G.

Psychiatr Pol. 2003 Jul-Aug;37(4):641-55. Polish.

PMID:
14560493
8.

Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study.

Chakos M, Patel JK, Rosenheck R, Glick ID, Hammer MB, Tapp A, Miller A, Miller D.

Clin Schizophr Relat Psychoses. 2011 Oct;5(3):124-34. doi: 10.3371/CSRP.5.3.2. Erratum in: Clin Schizophr Relat Psychoses. 2012 Jan;5(4):184. Miller, Del [added].

PMID:
21983496
9.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
10.

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2011 Feb;65(2):189-210. doi: 10.1111/j.1742-1241.2010.02587.x. Epub 2010 Dec 3. Review.

PMID:
21129135
11.

Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study.

Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, Andersson HM, Meulien D; Study 132 Investigators.

J Clin Psychiatry. 2007 Jun;68(6):832-42.

PMID:
17592906
12.

Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study.

Amsterdam JD, Hooper MB, Amchin J.

J Clin Psychiatry. 1998 May;59(5):236-40.

PMID:
9632034
14.

Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.

Jakubovski E, Carlson JP, Bloch MH.

J Clin Psychiatry. 2015 Nov;76(11):1535-45. doi: 10.4088/JCP.14m09320.

PMID:
26581028
15.

[Optimal Antipsychotic Dose and Dosing Interval in the Treatment of Schizophrenia].

Takeuchi H.

Seishin Shinkeigaku Zasshi. 2015;117(7):562-7. Review. Japanese.

PMID:
26552322
16.

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M.

J Clin Psychiatry. 2008 May;69(5):817-29.

PMID:
18466043
17.

Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial.

Pae CU, Kim JJ, Lee CU, Lee SJ, Lee C, Patkar AA, Masand PS, Paik IH.

J Clin Psychiatry. 2007 Mar;68(3):399-405.

PMID:
17388709
18.

A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder.

Honer WG, MacEwan GW, Gendron A, Stip E, Labelle A, Williams R, Eriksson H; STACK Study Group.

J Clin Psychiatry. 2012 Jan;73(1):13-20. doi: 10.4088/JCP.10m06194. Epub 2011 Jun 14.

PMID:
21733490
19.

Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia.

Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meulien D; Study 147 Investigators.

Curr Med Res Opin. 2008 Jan;24(1):21-32.

PMID:
18021496
20.

A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.

Whitmyer VG, Dunner DL, Kornstein SG, Meyers AL, Mallinckrodt CH, Wohlreich MM, Gonzales JS, Greist JH.

J Clin Psychiatry. 2007 Dec;68(12):1921-30.

PMID:
18162024

Supplemental Content

Support Center